Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rupitasertib - Evexta Bio

Next Previous
Drug Profile

Rupitasertib - Evexta Bio

Alternative Names: DIACC-3010; M-2698; MSC-2363318A

Latest Information Update: 24 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EMD Serono
  • Developer EMD Serono; Evexta Bio
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 70 kDa ribosomal protein S6 kinase inhibitors; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I HER2 positive breast cancer; Solid tumours
  • Preclinical Gastric cancer; Glioblastoma; HER2 negative breast cancer

Most Recent Events

  • 22 Apr 2024 Preclinical trials in HER2-negative-breast-cancer in France (PO) before April 2024
  • 22 Apr 2024 Pharmacodynamics data from preclinical in HER2 negative breast cancer released by Evexta Bio
  • 22 Apr 2024 Evexta Bio plans a phase II trial for HER2 negative breast cancer (Combination therapy, Late stage disease) in Q4 in 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top